Patent intelligence · US
US 11926625
HPK1 antagonists and uses thereof
HPK1 antagonists and uses thereof
Patent details — US 11926625
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 12, 2024
- Expiration
- Mar 7, 2044
- Applicant
- Nimbus Saturn, Inc.
- Claims
- 17
- CPC classes
- A61P, A61P31/12, A61P35/00
Quick answer
US 11926625 (HPK1 antagonists and uses thereof) is held by Nimbus Saturn, Inc.. Status: granted. Granted Mar 12, 2024. Expires Mar 7, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Nimbus Saturn, Inc.
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61P, A61P31/12, A61P35/00
More from Nimbus Saturn, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12310968
Chiral diaryl macrocycles and uses thereof
granted -
US 12252488
HPK1 antagonists and uses thereof
granted -
US 12215105
HPK1 antagonists and uses thereof
granted -
US 12187739
Diaryl macrocycle polymorph
granted -
US 12071442
Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
granted -
US 11981684
Macrocyclic compounds and uses thereof
granted -
US 11802292
Modified orthopoxvirus vectors
granted
Frequently asked questions
What is US patent 11926625?
US 11926625 (HPK1 antagonists and uses thereof) is held by Nimbus Saturn, Inc.. Status: granted. Granted Mar 12, 2024. Expires Mar 7, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11926625?
Nimbus Saturn, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 40 pharmaceutical patents for this assignee.
When does US 11926625 expire?
Our index shows an expiration date of Mar 7, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.